Canaccord analyst Whitney Ijem initiated coverage of Verve Therapeutics with a Buy rating and $29 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VERV:
- Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
- Verve Therapeutics reports new data from study of VERVE-201
- Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates
- Verve Therapeutics reports Q4 EPS (67c), consensus (76c)
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results